

#### **Center for AIDS Research Request for Applications**

APPLICATION DEADLINE: October 15th, 2015 by 5 PM

#### **Purpose**

The purpose of this funding opportunity is to support new HIV/AIDS pilot studies that focus on **HIV RNA** and **RNA** in **HIV/AIDS-associated conditions** with the purpose of developing preliminary data for use in future grant applications.

#### **Background and Scientific Areas of Interest**

The mission of the CFAR is to provide leadership, services and infrastructure necessary to: establish multidisciplinary collaborations that achieve high-impact discoveries; support the early career development of diverse young HIV/AIDS investigators; and to establish a distinctive scientific identity, placing the University of Rochester at the forefront of HIV/AIDS research.

Submitted applications should seek to expand our understanding of HIV RNA and develop new therapeutic strategies for targeting HIV at the RNA level - (i) directly targeting HIV RNA structures; (ii) improving our understanding of HIV RNA structure and function; (iii) preventing HIV-1 recombination (and thus its ability to develop drug resistance) and (iv) reactivating latent viral reservoirs.

#### **Eligibility**

All University of Rochester faculty may apply (including Research Assistant Professors). Faculty new to HIV/AIDS, and junior investigators are especially encouraged to apply. **New collaborations between HIV-focused investigators and RNA-focused investigators are especially encouraged.** Applications with foreign sites/involvement cannot be supported under this RFA.

#### **Awards**

Awards are for one year with maximum funding per application of \$50,000 Direct Costs.

#### **Application Instructions**

Applications must be submitted to Laura Enders, <u>Laura\_Enders@urmc.rochester.edu</u>, before or on **October**15<sup>th</sup>, 2015 by 5 PM. Applicants are encouraged to submit electronically as an attachment in pdf format.

# Application Requirements: Modified PHS 398 face page (page 4 of these guidelines) Abstract NIH-format biosketch for PI, co-investigators and mentors Updated Other Support for PI only Research Plan (limited to 3 pages): The Research Plan consists of items noted below, as applicable. It should be self-contained and include sufficient information to evaluate the project, independent of any other document (e.g., previous

- Specific Aims
- Research Strategy (Significance, Innovation and Approach)

application). Be specific and informative, and avoid redundancies.

Timeline

Human Subjects and Animals (no limit):
The Human Subjects and Animals Plan consists of items noted below, as applicable. It should be self-contained and include sufficient information to evaluate the project, independent of any other document (e.g., previous application). Be specific and informative, and avoid redundancies.
- Protection of Human Subjects
- Vertebrate Animals
Plans for Future Funding (limited to 1 page):
<ul> <li>Provide a short outline of how the pilot will develop into a NIH-funded grant. It should include the proposed hypothesis and specific aims intended for a NIH grant application as well as the projected timeline for submission.</li> </ul>
Data Analysis Plan (half-page limit):
<ul> <li>Provide a brief data analysis plan and identify if bioinformatics support is needed for data collection and management.</li> </ul>
Mentoring Plan (as applicable):
<ul> <li>Identify a primary mentor and provide a clearly delineated mentoring plan, including frequency and methods. The plan should identify long-term needs and goals in order to establish a successful independent academic career within the next 2 to 5 years.</li> </ul>
Budget (limited to 1 page using PHS 398 Form Page 4, providing a detailed description of supplies and other expenses within the form page):
<ul> <li>Limited to \$50,000 direct costs.</li> <li>Unless exceptional circumstances, funds may not be used to support faculty salary but the budget must</li> </ul>
identify the proposed effort.
- Funds may not be used for travel to professional meetings or equipment.
<ul> <li>Funds may be used to support research supplies and expenses, travel to collect data and other non-faculty salary.</li> </ul>
- If applicable, identify other sources of support that will be used to complete the pilot project.
Bibliography

#### **Submission and Review Process**

This is an internal competition for NIH-funds already awarded to the CFAR. **ORPA review and sign-off is not required but departmental review and approval should be sought.** Proposals will be reviewed by a faculty committee and will be assigned a priority score in accordance with these categories:

- Significance
- PI, Scientific Team & Environment
- Innovation and Multidisciplinary
- Experimental Approach
- Responsiveness to the terms of this RFA
- Probability of future NIH funding

A summary of the reviewers' comments will be provided once the review process has been completed

#### **Award Process**

CFAR will notify selected investigators via email within 1-2 weeks of the application deadline. Funding will not be released until all UR and NIH regulatory requirements have been met including IRB, IBC and IACUC

approvals as applicable. Upon receipt of all required documentation, the CFAR will issue a formal internal Notice of Award.

#### **Reporting Requirements**

CFAR will be reporting to NIH the outcome of this award for a period of no less than 5 years. Routine reporting is thus required of the investigator and should be comprised of a written report, which must include the following:

- Status of the work supported by pilot grant
- Statement regarding resulting grant applications, publications, presentations and inventions
- Update regarding plans for future funding resulting from the project

Award recipients will also be asked to present their projects and results at a CFAR sponsored seminar and/or annual World AIDS Day Scientific Symposium.

#### Inquiries:

CFAR Director – Steve Dewhurst CFAR co-Director – Mike Keefer Administrator – Laura Enders

P: 585-273-2939 F: 585-473-9573

http://www.urmc.rochester.edu/cfar/

## Grant Application UR CFAR 2013 HIV/RNA Pilot Application

1a. TITLE OF PROJECT					
2a. PRINCIPAL INVESTIGATOR		2b.DEGREE(S)		2c. NEW INVESTIGATOR	
2d. POSITION TITLE	2e. DEPARTMENT, MAJOR SUBDIVISION (if applicable)				
2f. TELEPHONE TEL ext:	2g. MENTOR				
Email:					
3. ADDITIONAL INVESTIGATORS (if applica	able)				
NAME		MAJOR SUBDIVISION	(if applicable	e)	
4a. HUMAN SUBJECTS RESEARCH	4b. RESEARCH EXE	MPT			
☐ No ☐ Yes	☐ No ☐ Ye	s If yes, exemption #			
4c. STATUS OF IRB SUBMISSION/APPROVA	AL		4d. CLINICA	L TRIAL	
Approved Submitted, review	v pending No	t yet submitted	☐ No	Yes	
5a. VERTEBRATE ANIMALS	5b. STATUS OF IACU	JC SUBMISSION/APPR	ROVAL		
☐ No ☐ Yes	Approved	Submitted 1	Not yet subm	itted	
6a. BIOHAZARD SAFETY			6b. HUMAN	I EMBRYONIC STEM CELL	
Will the project use any materials that wou	ıld require IBC approv	val: No Yes	☐ No	Yes	
7a. PROPOSED PROJECT PERIOD	7b. FUNDS REQUE	ESTED	7c. PROPC	SED SUBCONTRACT	
			☐ No	Yes	

#### **CFAR PROPOSAL SIGN-OFF FORM**

THIS FORM MUST BE COMPLETED AND SUBMITTED TO THE UR-CFAR WITH YOUR PILOT PROPOSAL AFTER ALL NECESSARY SIGNATURES HAVE BEEN OBTAINED. THIS FORM DOES NOT NEED TO BE SUBMITTED TO ORPA.

Drin	oinal Invoc		UF	R Finan	cials	UR Financials Cost Center
Principal Investigator (PI)/Contact PI Please check if this is a Multiple PI project (as defined by NIH) Other Multiple PIs/Co-PIs:						
Proj	ject Title					
Fun	ding Op (N	lumber/Title)				Award mechanism (R01, K08, CAREER)
		t Date End DateTotal Proje				
					val	Current UR Financials FAO (if applicable): GR
F&A	(Indirect)	Rate Award Type:			Co	ontract Subcontract/subaward
Pur	pose:	Research Clinical Research Training		•		Service
Proj	ject Locatio	on:   On-Campus   Off-Campus   If off-cam	pus, location	ı		
	ADMIN	ISTRATIVE AND POLICY CONSIDERATIONS (MUST B	SE COMPLE	TED B	Y PI)	- Please explain "yes" responses on additional sheets
	N	IOTE: All Co-Investigators, and other named investig	ators, MUS	T comp	lete	Section A ("Additional Signatures Certification")
Yes	No		Yes		13	. If you have acquired new financial interests since your last
⊒у	□n 1.		Шу	···	13.	disclosure, have you reported these to the institution?
		component with clinical procedures?  If "Yes", complete Section B (on page 4).	<b>Yes</b> □y		1/	. For NIH proposals, do all investigators agree to comply with the
<b>□</b> у	□n 2.	Does this project require additional/new space or	_			NIH Public Access Policy? Please see the NIH Policy for details
		renovation/modification of current space or facilities? Check all that apply:	□у	□n	15.	Is this an Individual NRSA (F-awards) Fellowship? If yes, complete the Individual Fellow and Faculty Mentor Certification
		Equipment/Utility support Additional, New or				for NIH F-awards Certification Individual Fellow and Faculty
		Renovated Space If yes, include an explanation on amount of space needed, cost and source of funds.	□у	Πn	16	Mentor Certification for NIH F-awards.  Are you currently debarred or suspended from doing business
<b>□</b> у	□n 3.	Does this proposal involve cost sharing or matching	Шу		10.	with the federal government or excluded from Medicare or other
		funds? If yes, complete below: -Total Amount of cost sharing				federal/state health care programs, or are you currently in default on any federal student loans?
		-Type of cost being sharedPlanned cost share UR Financials FAO(s)	□у	□n	17.	Have you engaged in lobbying activities using federal funds to influence any federal employee in connection with this
⊐y	□n 4.	-If the cost sharing is <b>Third Party Cost Sharing</b> , attach Pre-award THIRD PARTY COST SHARING FORM Will research use human subjects?	а Пу	□n	18.	proposal?  If funded, will other individuals be authorized to sign for purchases necessary for the project? If yes, name authorized individuals:
⊒y X	□n 5. □n 6.	Will research use animals? Will research use radioactive materials or isotopes?	□у	П.	10	. Is this proposal a collaborative inter-school/college program with
∃y ∃y ∃y	□n 7.	Will research use human embryonic stem cells?	Шу	U''	19.	sharing of indirect cost recovery? If yes, attach completed copy
□y	□n 8.	Are you requesting less than the maximum F&A costs as allowed by the sponsor's written policy?	□у	Πn	20	of Sharing of Indirect Cost Recovery form.  Does the project involve international partnerships or activities
<b>□</b> у	□n 9.	Will there be subcontracts to other institutions?	Шу	···	20.	in foreign countries? Country name:
⊒y	□n 10	Number? Is any program income anticipated under this project?	□y	□n	21.	Will the work involve the transfer of technology and/or
∃y		Do you have consulting arrangements, line	Пи	п.,	22	materials overseas?  Identify the CLASP-certified individual(s) who will have
		management responsibilities, substantial equity holdings with the sponsor, subcontractor, or potential vendor?	□у	ш <u></u>	22.	functional responsibility for oversight of this project, should it be funded.
⊐y	□n12.	Have you submitted an annual conflict of interest disclosure statement?				(Signature or initials of this individual recommended)
		PRINCIPAL INVES	TICATORS	, CEDT	IEIC	ATION
m si m	nust also in upplementa nade in the	elow the Principal Investigator(s) (Pls) certify that the abounclude signatures of all investigators in Section A (pa	ve is accurate ge 3 of this lidition, the Pally to crimina	e and o form). I(s) und al, civil,	omp The dersta or a	olete to the best of the PIs' knowledge. This certification be PI certifies the proposal (including any subsequent and that any false, fictitious, or fraudulent statements or claims dministrative penalties. The PI(s) agrees to accept
Prin	icipal Inves	etigator(s):				Date:
		REQUIRED SIGNATURES: (PLEASE SEE REVER	RSE FOR AL	DITIO	NAL	SIGNATURES WHICH MAY BE REQUIRED)
Dep	ot Chair:	Date:	Cost Center	Chief:		Date:
			Director of M	ledical	Cent	ter
nea	III	Date:	Space Plann (required for		ıl Ce	Date: enter if "Yes" has been checked on consideration 2 above)
Г	Form Rev	, 01/01/15 For O	RPA use or	nlv:		

Date:

ORPA RA:

#### **OBTAIN FOLLOWING SIGNATURES AS APPLICABLE TO THIS PROPOSAL:** Yes No □n A. Is proposed project using space or facilities of Strong Memorial Hospital? If yes, obtain Signature of SMH Senior Director for Finance Пν (x5-3033 - Room 1-2412): Will project require resources of the University Vivarium? If yes, please list the animal species □y □n B. estimated maximum number of each species housed at one time and send a copy of the signoff form to the attention of the Vivarium Director, Box 674. $\square$ у □n C. Will project require resources of the CRC? If yes, obtain Signature of CRC Director: □y □n D. Will project require services of the Department of Biostatistics and Computational Biology? If yes, obtain Signature of Chair, Department of Biostatistics and Computational Biology: Пν ☐n E (a). Will this project include pathogens, recombinant DNA, human blood, body fluids or tissue, virus vectors, human cell lines or generation of transgenic animals via recombinant DNA technology or interbreeding? For additional information, consult the IBC Webpage. Пν ☐n E (b). Will this project involve an OSHA recognized carcinogen? (2-Acetylaminofluorene, 4-Aminodiphenyl, Benzidine, bis-Chloromethyl ether, 3,3'-Dichlorobenzidine (and its salts), 4-Dimethylaminoazo-benezene, Ethyleneimine, methyl chloromethyl ether, alpha-Naphthylamine, beta-Naphthylamine, 4-Nitrobiphenyl, N-Nitrosodimethylamine, beta-Propiolactone) If answer to question E(a) or E(b) is marked "Yes", please send a copy of this completed signoff form to the attention of the IBC Program Coordinator, Environmental Health & Safety, RC Box 278878. $\square$ v □n F. Will faculty or staff from other University departments, divisions, or units participate in this project or will resources of another department.

#### **DESCRIPTION OF PROPOSAL SIGN-OFF RESPONSIBILITIES**

unit or office (see below) be used? If yes, obtain signature of Participating Department Chair(s), Dean(s), or Director(s):

Signature

Signature

Signature

**PRINCIPAL INVESTIGATOR/MULTIPLE PI:** The PI/Multiple PI is the initiator and director of the proposed program. The PI's/Multiple's PIs' signature(s) indicates that he/she/they will adhere to University and sponsor policies affecting the project, including completion of an Employee Intellectual Property Agreement and conflict of interest disclosure, monitoring of expenditures and the submission of reports required by the sponsor and the University.

**DEPARTMENT CHAIR, DIVISION/UNIT CHIEF:** These signatures mean that agreement has been reached regarding the amount and type of departmental resources that will be required to assist a PI in completing a project. If new space, personnel, or renovations are required, further discussion with the appropriate Dean's office will be necessary. This signature also confirms receipt of the annual conflict of interest disclosure and, where required, the supplemental disclosure and certifies that review will be complete and conflicts resolved, if any, prior to award.

**DEAN:** The Dean's signature means that agreement has been reached regarding the amount of School/College resources required to support the program. The Dean ensures that appropriate salary and pooled costs are requested in the proposal. As well, the Dean participates in discussions of new space or renovations required to complete a project.

THIRD PARTY COST SHARING: A complete Pre-Award Third Party Cost Sharing is required at the time of proposal to indicate the Third Party's concurrence with their cost sharing responsibilities.

#### ADDITIONAL REVIEW AND/OR OTHER SIGNATURES WHICH MAY BE REQUIRED DEPENDING UPON THE NATURE OF THE RESEARCH:

**RESOURCES OF OTHER DEPARTMENTS, UNITS OR OFFICES:** Projects that require resources of other University departments or offices require approval of the appropriate signatory. At the Medical Center, examples include Blackboard Online Learning, Curricular Affairs/Office of Medical Education, etc.

VIVARIUM: All University projects using animals must be reviewed by the University Committee of Animal Resources (UCAR, x5-1693).

**BIOHAZARDS**: Projects which propose the use of potential biohazards, including recombinant DNA and carcinogens, must be reviewed by the Executive Secretary of the Biosafety Committee, 685 Mt Hope Ave., x5-3241. This signature is required to comply with federal and state regulations covering biohazards.

**BIOSTATISTICS AND COMPUTATIONAL BIOLOGY SERVICES:** Projects that involve biostatistics services must be approved by the Department of Biostatistics and Computational Biology, Saunders Research Bldg. Room 4106, x5-2407. This signature ensures that adequate costs and professional effort have been included to support biostatistical studies.

**STRONG MEMORIAL HOSPITAL:** Projects which involve facilities, services, or training programs of Strong Memorial Hospital require the signature of the Senior Director for Finance, Room 1-2412, Medical Center, x5-3300.

**CLINICAL RESEARCH CENTER:** Projects which will require beds, space, or staff of the Clinical Research Center should be reviewed by the Director of the Clinical Research Center. Room 1.502, Saunders Research Building, x5-0674.

**EXPLANATION OF THE ITEMS FROM FRONT (use additional sheets)** 

Faculty and Dept. Name (printed)

Faculty and Dept. Name (printed)

Faculty and Dept. Name (printed)

### Section A: Additional Signatures Certification new, competing, and non-competing (progress reports) applications

In signing below the following Investigators certify that:

- they have submitted an annual conflict of interest disclosure statement;
- there are no new financial interests to report (if there are new financial interests that have not been disclosed, the investigator must report these prior to proposal submission); and
- they are not currently debarred or suspended from doing business with the federal government or excluded from Medicare or other federal/state health care programs, or that they are not currently in default on any federal student Loans.
- In addition, the Investigators understand that any false, fictitious, or fraudulent statements or claims made in the accompanying submission may subject the Investigators personally to criminal, civil, or administrative penalties. The Investigators agree to accept responsibility for the scientific conduct of the project and to provide the required progress reports if a grant is awarded as a result of this application.

Name	Signature	Role on Project (e.g. Pl, Res. Assoc.)

Form Rev. 01/01/15 Page 3

#### SECTION B: Prospective Reimbursement Analysis (PRA) (Note 1)

	If Question 1 in the <b>ADMINISTRATIVE AND POLICY CONSIDERATIONS</b> section was answered "Yes", please check one of the appropriate boxes below:						
	The clinical research study's clinical procedures constitute a clinical trial (i.e. there is an investigational drug, device or treatment). The PI has signed the following three (3) worksheets (copies are attached to this sign off form): PRA Template, Participant Grid/Billing Plan and Total Budget comparison worksheet (refer to Note 2 and Note 3).						
	□y	The clinical research study's clinical procedures constitute a clinical trial (i.e. there is an investigational drug, device or treatment) and the sponsor has indicated it will pay for all visits and procedures (i.e. nothing will be billed to third party insurance). The PI has signed the following two (2) worksheets (copies are attached to this sign off form): Participant Grid/Billing Plan and Total Budget comparison worksheet (refer to Note 3).					
	□y	The clinical research study is <u>not</u> a clinical trial (i.e. there is <u>not</u> an investigational drug, device or treatment). The PI has signed the following two (2) worksheets (copies are attached to this sign off form): Participant Grid/Billing Plan and Total Budget comparison worksheet (refer to Note 3).					
	PRINCIPAL INVESTIGATORS' CERTIFICATION  In signing below the Principal Investigator(s) certify that he/she has completed the Blackboard clinical trial training (Course CT-01).						
	Principal Investig	Date:					
	Timolpal invocing	ator(o) realino(o)					
<u>NOTE 1</u> :	defines a Prospect	tochester Clinical Research Standard Operating Procedures Regarding Financial Oversight and Billing Compliance ive Reimbursement Analysis as "the process of determining and documenting what procedures, items and tests in a ard of care or strictly related to research. This information is then used to determine the appropriate payer of such I).					
NOTE 2:	The PRA Template is a questionnaire that assists with the determination whether a clinical trial is a "Qualifying trial" as per Centers for Medicare and Medicaid Services guidelines. The PRA Template is a worksheet within the UR's Budgeting Workbook for clinical trials, accessible in the Clinical Trial Resources Share Point site (that is accessible through the link on this web page <a href="http://www.rochester.edu/ORPA/Clinical_Trial_Resources/index.html">http://www.rochester.edu/ORPA/Clinical_Trial_Resources/index.html</a> ).						
<u>NOTE 3</u> :	E 3: The Participant Grid/Billing Plan is an EXCEL worksheet on which is documented the proper payer for each clinical procedure for visit in a clinical research study plan. A Total Budget comparison worksheet allows comparison of the sponsor's financial offer to UR's internally prepared budget and indicates whether a potential deficit or surplus exists. The Participant Grid/Billing Plan and Total Budget comparison are worksheets within the UR's Budgeting Workbook for clinical trials, accessible in the Clinical Trial Resources Share Point site (that is accessible through the link on this web page:						

Form Rev. 01/01/15 Page 4